Paul H. Kim, Ph.D. · Bioengineer & Cell Biologist

Most children with Hutchinson–Gilford progeria syndrome die of cardiovascular disease, and this study asks whether progerin acting inside cardiomyocytes is enough to drive the heart disease of HGPS.

The authors built a tamoxifen-inducible mouse model that expresses progerin only in cardiomyocytes, which developed myocardial fibrosis, cardiomyocyte hypertrophy, reduced cardiac output and a shortened median lifespan.

These hearts had less of the m⁶A RNA methylation writers METTL3 and METTL14, a reduction also seen in Lmna G609G and Zmpste24-deficient progeroid mice and in naturally aged mouse hearts.

In cultured primary cardiomyocytes, knocking down Mettl3/14 lowered the calcium-handling transcript Casq2 and raised senescence (Cdkn1a, Cdkn2a) and interferon (Ifna, Ifnb) transcripts.

Restoring METTL14 in the heart with an AAV9 vector partially reduced fibrosis and cardiac dysfunction in progeroid mice, and the authors report longer median survival.

All evidence comes from mice and cultured cells and the rescue was partial, so whether boosting m⁶A writers could help children with HGPS remains untested.

Cells that squeeze through tight spaces must protect their nucleus from the actomyosin forces that pull it along, and this study identifies septin filaments as a buffer for those forces.

In cancer cell lines migrating through narrow pores, filaments containing SEPT9 aligned with perinuclear actomyosin cables, which carried more tension as pores narrowed.

Depleting SEPT9 increased actin stress and caused nuclear envelope ruptures, both during confined migration and when myosin II was hyperactivated in non-migrating cells, including Sept9-knockout mouse fibroblasts.

After confined migration, SEPT9-depleted cells showed more DNA breaks, nuclear blebs, micronuclei and cell death, defects rescued by SEPT9 isoform 1.

Clinicogenomic data associated SEPT9 amplification with less genomic alteration in aggressive breast tumors, leading the authors to propose that septins help metastatic cells avoid lethal nuclear damage.

The mechanistic work is in cultured cells and the tumor link is correlational, and whether septins also shield lamin-deficient or aged nuclei, which are prone to rupture, has not been examined.

Moderately cold temperatures extend lifespan in many species, and this study traces how cold produces that benefit in the nematode Caenorhabditis elegans.

Cold raised the biopterin-synthesis enzyme CAT-4 (GCH1 in humans), increasing production of dihydrobiopterin (BH2) in muscle, which is transported to the intestine and neurons and converted there by DHFR-1 into the cofactor tetrahydrobiopterin (BH4).

BH4 supports phenylalanine hydroxylase and tyrosine synthesis, and this axis was required for cold-induced longevity and protected against disease-related protein aggregation and neuronal dysfunction during ageing.

Increasing BH2 synthesis only in muscle was enough to extend lifespan and suppress aggregation in distant tissues, even at normal or elevated temperatures.

In human cells, BH2 or tyrosine supplementation reduced aggregation of polyQ-expanded proteins associated with Huntington's disease and of ALS-linked mutant TDP-43 and FUS.

The lifespan results are in worms and the human data come from cultured cells, so whether the BH2–BH4 pathway influences ageing or neurodegeneration in mammals remains unknown.

Insulin lowers blood glucose but does not remove the surplus energy that drives weight gain in type 2 diabetes with obesity, and this study tests an implant that removes glucose chemically instead.

The ECHO device uses platinum-decorated gold nanoclusters embedded in graphite felt to oxidize blood glucose electrocatalytically into gluconate, which is cleared by the kidneys.

In type 2 diabetic mice, low-power wireless activation restored glucose homeostasis within 1 hour and, over 6 weeks of treatment, reduced body weight and triglycerides while raising circulating free fatty acids and ketone bodies.

The authors detected no hypoglycemia or adverse physiological, inflammatory or behavioral effects, and coupling the device to a commercial continuous glucose monitor enabled smartphone-controlled closed-loop operation.

All in vivo testing was in mice and the device has not been tried in people, so long-term safety, durability and scale-up to human glucose loads remain open questions.